Plotkin and Koprowski would do just that: in 1969, they developed the RA27/3 rubella vaccine, the first of many vaccines using WI-38 cells.
Hayflick's career, however, was tarnished by his involvement in a protracted dispute with the Wistar Institute and the National Institutes of Health over claims to the WI-38 cells.
The first is the many individuals who volunteered their bodies, knowingly or unknowingly, to develop the WI-38 cells and to test the vaccine.
Using human fibroblast WI-38 cells
and the transformed WI-38RA cells, this study explored apoptosis levels as well as cell viability using Hoechst/propidium iodide staining following treatment with reovirus for 2, 8, 24, 48, and 72 h.